No Data
Individual Investors Who Own 34% Along With Institutions Invested in AbCellera Biologics Inc. (NASDAQ:ABCL) Saw Increase in Their Holdings Value Last Week
AbCellera to Present at Upcoming Investor Conferences in December and January
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
Bloom Burton Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $9